Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease by Bordelon, Yvette M. et al.
SAGE-Hindawi Access to Research
Parkinson’s Disease
Volume 2011, Article ID 967839, 6 pages
doi:10.4061/2011/967839
Clinical Study
Medication Responsiveness of Motor Symptoms in a
Population-Based Study of Parkinson Disease
Yvette M. Bordelon,1 Ron D. Hays,2,3,4 StefanieD. Vassar,1,5 Natalie Diaz,6
Jeff Bronstein,1,5 andBarbara G.Vickrey1,5
1Department of Neurology, David Geﬀen School of Medicine at UCLA, Los Angeles, CA 90095-7334, USA
2Department of Medicine, UCLA Division of General Internal Medicine and Health Services Research, Los Angeles,
CA 90095-1736, USA
3UCLA School of Public Health, Los Angeles, CA 90095-1772, USA
4RAND, Santa Monica, CA 90407-2138, USA
5Parkinson’s Disease Research, VA Greater Los Angeles Healthcare System, Education and Clinical Center, Los Angeles,
CA 90073, USA
6Department of Neurology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
Correspondence should be addressed to Yvette M. Bordelon, ybordelon@mednet.ucla.edu
Received 16 August 2011; Revised 4 October 2011; Accepted 5 October 2011
Academic Editor: Jan O. Aasly
Copyright © 2011 Yvette M. Bordelon et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
We assessed degree of Parkinson disease motor symptom improvement with medication among subjects enrolled in an ongoing,
population-based study in Central California. The motor section of the uniﬁed Parkinson disease rating scale (UPDRS) was
performed on subjects in both OFF and ON medication states, and diﬀerence between these scores was used as an indicator
of symptomatic beneﬁt. Higher OFF minus ON scores correlated with more severe baseline symptoms. There was equivalent
improvement on the motor UPDRS scale for subjects divided according to medication classes used: levodopa alone 7.3 points,
levodopa plus other medications 8.5 points, and dopamine agonists but not levodopa 6.1 points. In addition, there was no
diﬀerenceinthemagnitudeofimprovementwhensubjectsweredividedaccordingtoParkinsondiseasesubtype,deﬁnedastremor
dominant, akinetic-rigid, or mixed. In this community-based sample, these values are within the range of a clinically important
diﬀerence as deﬁned by previous studies.
1.Introduction
Clinical trials in Parkinson disease document improvement
of motor features of the disorder using standardized rating
scales, in particular the uniﬁed Parkinson disease rating scale
(UPDRS). However, subjects participating in these studies
generallyseekcareintertiarycarecenters;duetostrictproce-
dures implicit in the conduct of clinical trials, such subjects’
medications and response to medications are optimized and
tightly controlled. To assess PD motor symptom control in
a community-dwelling population, we used a cohort of PD
subjects followed in a population-based study of PD risk and
predictors of progression [1] .T h e s es u b j e c t sr e s i d ei nr u r a l
counties in Central California, and their PD care is managed
by local general neurologists [1]. Subjects were examined by
movement disorder specialists using UPDRS Motor exams
in the OFF state and again after their PD medication dosage
(ON exam) as prescribed by their community clinician. The
diﬀerence in Motor UPDRS scores between the OFF and
ON states was used to document the degree of PD symptom
improvement. It has been previously established by Shulman
and colleagues that Motor UPDRS OFF-ON diﬀerences
are clinically important with ranges of 2.3–2.7 points for
minimal CID (clinically important diﬀerence) and 10.7–10.8
forlargeCID[2].WeinvestigatedwhethertheMotorUPDRS
OFF-ON diﬀerences found in our study were within these
ranges and if the degree of improvement was associated
with any factors in particular. Comparisons were made2 Parkinson’s Disease
according to medication class used as levodopa has more
pronounced symptomatic beneﬁt than dopamine agonists
and might result in greater OFF-ON diﬀerences [3, 4]. We
alsoassessedwhetherPDsubtypesmayresponddiﬀerentially
to medications, knowing that akinetic-rigid PD typically ex-
hibits a more rapid decline than tremor-dominant PD and is
less responsive to treatments [5].
2. Methods
Subjects with idiopathic Parkinson disease (PD) identiﬁed
within the prior three years were enrolled in the Parkinson’s
environment and gene (PEG) study on risk factors of inci-
dent PD [1]. General neurologists practicing in and around
Kern, Tulare, and Fresno counties referred PD patients to
the PEG study, and among referrals, approximately 45% fell
within the three-year diagnosis duration required for study
entry. Overall, 28 of the 31 neurologists in these counties
(90%) referred patients. Study subjects completed question-
naires, and their diagnosis was conﬁrmed by a movement
disorders neurologist. Study participants returned to receive
routine care for their PD by their local general neurologists.
Enrolled subjects were then invited to participate in a follow-
up study. Of the 371 subjects initially enrolled into PEG,
254 were eligible and provided written, informed consent
for the current study (UCLA Institutional Review Board no.
G06-07-055), and were reevaluated as part of the follow-
up study between June, 2007 and June, 2009. Subjects
provided updated information, including medications, and
underwent two motor examinations by one of four board-
certiﬁed neurologists with movement disorders fellowship
training experienced in UPDRS administration. Examiners
were unaware of this study’s planned analyses at the time of
data collection.
The UPDRS Motor examination section and Hoehn and
Yahr staging were performed for each subject in both the
practically deﬁned OFF medication state (patients willing
and able to withhold all PD medications for at least 12
hourspriortoassessment)andtheONmedicationstate(one
hour after taking their usual morning PD medications that
same day). The motor section contains 27 items scored 0
(no impairment) to 4 (severe impairment) with a possible
scale score range of 0–108 [6]. Diﬀerence in OFF and ON
medication state Motor UPDRS scores was examined by ON
score and by OFF score using scatterplots.
Subjects were divided into three subgroups by medica-
tion used: levodopa only, levodopa plus other PD medica-
tion (including monoamine oxidase-B inhibitors, dopamine
agonists, catechol-o-methyl transferase inhibitors, amanta-
dine, or trihexyphenidyl), and dopamine agonists without
levodopa plus other PD medication. The diﬀerence between
OFF and ON Motor UPDRS exam scores was calculated for
each subject. One-way analysis of variance (ANOVA) among
medication subgroups by diﬀerence between OFF and ON
state Motor UPDRS exam scores was determined. Chi square
analysis of Hoehn and Yahr stage was performed among
medication subgroups and PD subtypes.
PD subtypes were deﬁned on the basis of the OFF state
Motor UPDRS exam according to criteria used for subtype
analysis of the initial PEG population, with minor modiﬁca-
tion [1]. Tremor-dominant PD was deﬁned as a ratio >1.0 of
tremor score (sums of items 20 and 21 divided by 7) divided
by the akinetic/rigid score (sum of items 22–31 divided by
18).Akinetic-rigidPDwasassignedwhenthisratiowas<0.8,
and mixed subtype to subjects with a ratio between 0.8 and
1.0.
3. Results
Of 254 study participants, 193 completed both OFF and
ON PD medication assessments and were included in these
analyses. Of those excluded, 24 could not undergo an in-
person evaluation, 16 could not withhold morning medica-
tions (onlyONexam performed),and 21 completed only the
OFF evaluation, as they were not on PD medications (n =
12), did not bring their medications (n = 3) or no reason
was recorded (n = 6). Average age was 72.4 years (SD 9.2),
and there was a male (59%) and white (79%) predominance
as in the initial cohort [1]. Mean disease duration was 5.2
years (SD 2.3), and 82% of subjects were Hoehn and Yahr
stage 2 or higher (Table 1). Breakdown of medications used
and mean doses are provided in Table 2.
Scatterplots of the diﬀerence between OFF and ON
Motor UPDRS score against the OFF state (Figure 1(a))a n d
ON state (Figure 1(b)) score revealed that higher OFF Motor
UPDRS scores correlated with greater medication respon-
siveness (bigger improvement in Motor UPDRS scores from
OFF to the ON state) (test of slope P = 0.01). Thus,
there was clear improvement in motor symptoms with PD
medications, more pronounced in more advanced disease.
However, when medication response was plotted against ON
scores there was no signiﬁcant correlation (test of slope P =
0.46), indicating that most subjects achieved similar levels
of symptom control (equivalent ON scores) regardless of
underlying disease severity.
We next explored whether certain features determined
the degree of medication responsiveness in this community-
dwelling cohort of PD patients. Subjects were divided into
three groups according to PD medications used. One subject
was not categorized in this scheme, as they were on MAO-
B inhibitors alone. The majority of subjects (91%) were
on levodopa either alone or in combination with other PD
medications. Comparisons were made among medication
subgroups and ON, OFF, and diﬀerence between OFF and
ON Motor UPDRS scores (Table 3). Baseline OFF medica-
tion scores were lower (better) in subjects not on levodopa
(P<0.05 pairwise t-test), which is to be expected, as in
general, levodopa may be added later as disease progresses.
However, medication response as measured both by ON
scores and by OFF-ON scores was not diﬀerent across the
medication subgroups, with improvement in Motor UPDRS
scores ranging from 6.1–8.5 points. There was no diﬀerence
among medication subgroups in Hoehn and Yahr staging
(Table 3 Chi square).Parkinson’s Disease 3
Table 1: Sample demographics (n = 193).
Characteristic Total
N ( % )o rm e a n( S D )
Mean age, yrs, (SD) 72.4 (9.2)
Male, n (%) 114 (59.1)
White, n (%) 152 (78.8)
College education, n (%) 62 (32.1)
Married, n (%) (n = 190) 145 (76.3)
Employed full/part-time (%) 35 (18.1)
Mean duration of PD, yrs, (SD) 5.2 (2.3)
Mean Hoehn and Yahr stage, (SD) 2.7 (0.8)
Hoehn and Yahr stage, n (%)
Stage 1: Unilateral disease 24 (12.8)
Stage 1.5: Unilateral plus axial involvement 10 (5.3)
Stage 2: Bilateral disease, without
impairment of balance 72 (38.8)
Stage 2.5: Mild bilateral disease with
recovery on pull test 41 (21.8)
Stage 3: Mild-to-moderate bilateral
disease; some postural instability;
physically independent.
26 (13.8)
Stage 4: Severe disability; still able to walk
or stand unassisted 9 (4.8)
Stage 5: Wheelchair bound or bedridden
unless aided 5 (2.7)
Medication status, n (%)∗
Levodopa only 67 (34.9)
Levodopa and any other medication 108 (56.3)
Dopamine agonists without levodopa 17 (8.9)
PD subtype, n (%)
Tremor-dominant 33 (17.1)
Akinetic rigid 142 (73.6)
Mixed 18 (9.3)
∗One subject excluded because they were on MAO-B inhibitors alone.
In the analysis of OFF-ON Motor UPDRS score diﬀer-
e n c e sb yP Ds u b t y p e ,3 3s u b j e c t sw e r ec l a s s i ﬁ e da st r e m o r -
dominant, 142 as akinetic-rigid and 18 as mixed. The
akinetic-rigid subtype had higher Motor UPDRS scores in
the OFF and ON states than tremor-dominant or mixed
subgroups indicating greater disease severity (Table 4). Mean
daily levodopa dosage was not diﬀerent among the subtypes
(Table 4). However, the diﬀerence in OFF and ON scores was
the same across all subtypes, demonstrating that regardless
of motor symptom severity, PD medications led to similar
range of improvement of 7 to 8 UPDRS points. There was a
tendency for akinetic-rigid subjects to have a higher Hoehn
and Yahr stage indicative of more severe disease (Table 4 Chi
square), yet they responded to a similar degree as the other
subtypes. A subgroup analysis of only those subjects with
Hoehn and Yahr ≤2.5 demonstrated that the OFF-ON score
diﬀerences for tremor-dominant subjects was 7.4 and for the
akinetic-rigid subjects was 7.7, and it was thus even closer
Table 2: Medications (n = 193).
Medication status N (%)
Daily dosage
(mg) mean
(SD)
Levodopa only 67 (34.9)
Carbidopa/levodopa 43 (22.3) 513.9 (254.6)
Carbidopa/levodopa (Sinemet CR
or XR) 18 (9.3) 500.0 (205.8)
Levodopa and any other medication 108 (56.3)
Pramipexole 46 (23.8) 2.3 (1.7)
Ropinirole 33 (17.1) 7.3 (6.9)
Bromocryptine 2 (1.0) 2.5 (0.0)
Carbidopa/levodopa 80 (41.5) 557.6 (307.2)
Carbidopa/levodopa (Sinemet CR
or XR) 37 (19.2) 585.1 (296.9)
Amantadine 11 (5.7) 227.3 (46.7)
Trihexyphenidyl 4 (2.1) 5.5 (3.4)
Entacapone 23 (11.9) 747.8 (219.2)
Dopamine agonists without levodopa 17 (8.9)
Pramipexole 10 (5.2) 2.4 (1.4)
Ropinirole 7 (3.6) 8.6 (4.7)
in magnitude than for the entire sample that included those
with more severe PD.
4. Discussion
Medication response in a community-dwelling population
of PD subjects was assessed by performing Motor UPDRS
exams in the practically deﬁned OFF as well as ON states.
Subjects were examined after taking their usual prescribed
dose of PD medications; thus, there was no standardization
or specialist-directed optimization of medication regimens.
This is representative of the treatment obtained in a com-
munity setting outside of tertiary care centers. We found
that PD subjects with higher disease burden, evidenced by
higher Motor UPDRS OFF scores, had a greater response to
medications. The greater change may be in part a reﬂection
of regression to the mean. Thus, PD symptoms clearly im-
proved and to a greater degree when the baseline disease
manifestations were more severe. There was no similar trend
when symptom improvement was plotted against ON scores,
suggesting that medications were titrated to a similar level of
symptom improvement.
We did not identify a speciﬁc characteristic that allowed
for prediction of better response to medications or higher
diﬀerences between Motor UPDRS OFF and ON scores.
Subdivisionbymedicationclassesusedrevealedsimilarmed-
ication response. There was a trend toward less response in
thenolevodopagroup—whichcouldsupporttheknowledge
that levodopa elicits greater symptom improvement than
dopamine agonists or other medications [3, 4]—but this was
not statistically signiﬁcant. However, it must be noted that
whileweexaminedpatientsinthebestdeﬁnedOFFstate,this
onlystrictlyappliestolevodopa,astheotherPDmedications4 Parkinson’s Disease
Table 3: Total Motor UPDRS ON and OFF medication by medication status (n = 193).
Medication status∗
Levodopa only
(n = 67) mean (SD)
Levodopa and any
other medication
(n = 108) mean (SD)
Dopamine agonists
without levodopa
(n = 17) mean (SD)
ANOVA
P value
Total Motor UPDRS ON medication 17.3 (11.9)a 17.3 (10.4)a 14.8 (8.1)a 0.65
Total Motor UPDRS OFF medication 24.6 (12.1)a 25.8 (12.0)a 20.9 (7.5)b 0.26
Diﬀerence between ON and OFF 7.3 (4.6)a 8.5 (5.4)a 6.1 (4.6)a 0.11
Hoehn and Yahr–OFF medication N (%) N (%) N (%)
Chi-
square
P-value
1 4 (5.9) 4 (3.7) 2 (11.7) 0.76
1.5 3 (4.5) 8 (4.7) 1 (5.9)
2 23 (34.3) 35 (32.4) 6 (32.3)
2.5 22 (32.8) 27 (25.0) 5 (29.4)
3 10 (14.9) 20 (18.5) 3 (17.7)
4 2 (3.0) 10 (9.3) 0 (0.0)
5 3 (4.5) 4 (3.7) 0 (0.0)
Table 4: Total Motor UPDRS ON and OFF medication by PD subtype (n = 193).
PD subtype
Tremor-dominant
(n = 33) mean (SD)
Akinetic rigid
(n = 142) mean (SD)
Mixed
(n = 18) mean (SD)
ANOVA
P value
Total Motor UPDRS ON
medication 12.1 (7.8)a 18.9 (11.4)b 13.2 (5.1)a 0.001
Total fMotor UPDRS OFF
medication 19.3 (9.9)a 26.9 (12.1)b 20.9 (5.7)a 0.001
Diﬀerence between ON and OFF 7.2 (5.1)a 8.0 (5.4)a 7.7 (1.9)a 0.73
Levodopa dosage per day (mg) 551.6 (306.2)a (n = 32) 613.6 (285.4)a (n = 116) 569.6 (357.6)a (n = 14) 0.54
Hoehn and Yahr–OFF
medication N (%) N (%) N (%) Chi-square
P-value
1 5 (15.2) 5 (3.5) 0 (0.0) 0.003
1.5 5 (15.2) 4 (2.8) 3 (16.7)
2 14 (42.4) 42 (29.6) 8 (44.4)
2.5 5 (15.2) 46 (32.4) 3 (16.7)
3 3 (9.1) 27 (19.0) 4 (22.2)
4 1 (3.0) 11 (7.8) 0 (0.0)
5 0 (0.0) 7 (4.9) 0 (0.0)
UPDRS = Uniﬁed Parkinson’s Disease Rating Scale.
∗One subject excluded, because they were on MAO-B inhibitors alone.
a,bMeans within a row with diﬀerent letters diﬀer signiﬁcantly (P ≤ 0.05; pairwise t-test).
subjects were taking tend to have much longer half-lives.
Even levodopa would likely need to be eliminated for days
t ow e e k st oc o m p l e t e l yw a s ho u t[ 7, 8].
Subjects on dopamine agonist without levodopa had
lower medication OFF scores compared to the levodopa
groups which could be explained by an incomplete wash-out
of the dopamine agonist symptomatic beneﬁt given the
longer half-life of these agents. Alternatively, we may con-
sider that subjects on dopamine agonists without levodopa
may be in earlier stages of disease and thus have lower OFF
scores.WhilediseasestagingbyHoehnandYahrscoresacross
the three medication subgroups did not meet statistical
cutoﬀs for signiﬁcance, a slightly higher percentage of the
dopamine agonist without levodopa compared to the lev-
odopa subjects were in Hoehn and Yahr stages 1 and 1.5. No
dopamine agonist without levodopa subjects were in Hoehn
and Yahr stages 4 or 5.
In addition, all PD subtypes responded similarly to med-
ications regardless of baseline level of impairment. Akinetic-
rigid PD subjects had a higher Motor UPDRS OFF score
representing greater overall motor impairment and higher
Hoehn and Yahr stage (Table 4), yet these symptoms re-
sponded to a similar degree as tremor-dominant and mixed
subtypes. This is contrary to the report by Rajput et al.,Parkinson’s Disease 5
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Figure 1: (a) Scatterplot of total Motor UPDRS scores OFF PD
medication versus diﬀerence in total Motor UPDRS scores OFF
medication and ON medication (test of slope P = 0.01). (b)
Scatterplot of total Motor UPDRS scores ON PD medication versus
diﬀerence in total Motor UPDRS scores OFF medication and ON
medication (test of slope P = 0.46).
documenting a lower proportion of akinetic-rigid patients
responding to levodopa [5]. Accounting for this diﬀerence,
we consider that subjects in Rajput’s et al., study were not
assessedintheOFFandONmedicationstatesasinourstudy.
In addition, it must be considered that there may have been
greater measurable improvement of more severe symptoms
in the akinetic-rigid group or less measurable improvement
of less severe symptoms in the tremor-dominant group.
TheMotorUPDRSpointimprovementrangedfrom6.1–
8.5 among the various subgroups analyzed. We do not have
a comparison in the literature for whether this magnitude
of symptom control is similar to other community-based
patient populations. However, Shulman and colleagues have
reported that clinically important diﬀerences (CIDs, as
deﬁned as improvement notable to patients) in Motor
UPDRS scores in their tertiary care referral center were 2.3–
2.7 points (minimal CID), 4.5–6.7 points (moderate CID)
and10.7–10.8 points (largeCID) [2];analysisof theminimal
CID within a clinical trial population of early PD patients
participating in two dopamine agonist studies was estimated
to be 5 points on the Motor UPDRS scale [9]. On the basis
of these ranges, our subjects’ level of improvement on their
typical PD medication dosages falls within ranges that are
likely clinically signiﬁcant.
This study presents PD medication practices in a com-
munity dwelling population. M¨ oller and colleagues reported
on drug classes used in PD treatment in Germany from a
general population sample revealed that 94.2% of patients
were treated with levodopa with an average daily dose
of 599mg [10]. Sixteen percent of their PD population
under the age of 70 were on levodopa alone without us-
ing dopamine agonists, and thus they reported that best
treatment practices are not necessarily put into eﬀect in
the general population. They did not perform neurologic
examinations to ascertain level of medication response.
Schrag and Quinn described treatment in a community-
based population of PD patients speciﬁcally investigating the
occurrence of dyskinesias and motor ﬂuctuations, symptoms
that emerge later in disease typically [11]. Again, there was
no report of neurologic examination to document motor
symptom severity.
Recently, Josephs et al., reported on a new PD subtype
deﬁned as benign tremulous Parkinsonism which, is deﬁned
ashavingtremorastheinitialandmostprominentsymptom,
having mild nontremor symptoms, very mild progression of
disease over a long duration with absence of gait problems
and disability except for tremor [12]. We are unable to deter-
mine whether any of our tremor-dominant subjects ﬁt into
this diagnostic criteria given that slow disease progression
must be quantiﬁed for the diagnosis. Future assessments will
be performed to determine if this subtype can be identiﬁed
in our population to see if their treatment responses diﬀer
from other subtypes.
Our ﬁndings describing symptom responsiveness to PD
medications in a general community setting reveal that there
is clear improvement in symptom control irrespective of
medication classes used or subtype of PD. The degree of
symptom control is within a range determined to be clin-
ically meaningful by previous studies. Future studies will
investigate whether this degree of motor improvement cor-
relates with health-related quality of life.
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